Results 171 to 180 of about 2,196,057 (314)
Multi-institutional care is associated with improved survival in biliary tract cancer. [PDF]
Lal T +7 more
europepmc +1 more source
Preventing maltreatment in institutional care: A cluster-randomized controlled trial in East Africa. [PDF]
Hecker T +5 more
europepmc +1 more source
ABSTRACT Objectives Retrograde trans‐synaptic degeneration (rTSD) from posterior visual pathway lesions in multiple sclerosis (MS) is characterized by hemi‐macular ganglion cell‐inner plexiform layer (GCIPL) thinning and contralateral visual field loss.
Abdul Jaber Tayem +17 more
wiley +1 more source
Child mental health after institutional care in Azerbaijan: prevalence and correlates. [PDF]
Ismayilova L +7 more
europepmc +1 more source
Sex Representation in US Stroke Clinical Trials: A Decade of Trends and Challenges
ABSTRACT Objective Stroke remains a major cause of disability and mortality in the US, with significant sex‐based disparities, and females remain underrepresented in stroke clinical trials. We aimed to examine sex representation in US‐based stroke clinical trials, identify trial characteristics associated with higher female enrollment (≥ 50%), and ...
Chaitali Dagli +5 more
wiley +1 more source
Institutional Ownership and the Returns on Investment [PDF]
By examining a large number of Swedish listed firms, we analyse how institutional and foreign owners affect investment performance. To measure investment performance Mueller and Reardon’s (1993) marginal q is used, although derived directly from Tobin’s ...
Wiberg, Daniel +2 more
core
Quality Of Care In Dental Institutes [PDF]
openaire +3 more sources
Impact of an exercise and nutrition program on caregiver time with residents in institutional care-A secondary analysis. [PDF]
Wimo A +7 more
europepmc +1 more source
Long-Term Effects of Institutional Care and Enhanced Attachment Relationships on Close Adolescent Friendships. [PDF]
Tang A +5 more
europepmc +1 more source
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane +43 more
wiley +1 more source

